PPT-Simplification to Efavirenz-Tenofovir DF-Emtricitabine

Author : valerie | Published Date : 2024-07-01

ADONE Trial Simplification to EfavirenzTenofovir DFEmtricitabine ADONE Study Design Source Airoldi M et al Patient Prefer Adherence 2010411525 Study Design ADONE

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Simplification to Efavirenz-Tenofovir DF..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Simplification to Efavirenz-Tenofovir DF-Emtricitabine: Transcript


ADONE Trial Simplification to EfavirenzTenofovir DFEmtricitabine ADONE Study Design Source Airoldi M et al Patient Prefer Adherence 2010411525 Study Design ADONE Study Background. Lexical Simplification. A subtask of text simplification. Replacing words or short phrases by . simpler variants. in a context aware fashion. Motivation. To reach out to wider range of readers having limited vocabulary. GENERIC ARVs. Tim Horn. Treatment Action Group. tim.horn@treatmentactiongroup.org. Federal AIDS Policy Partnership Meeting. December 2014. Patents and Exclusivity 101 . Myriad Policies. Patents issued >1996 have term of 20 years. By Scott . Kominers. And. Lukens Orthwein. Computational Complexity. Eliminating “Bad” . Equilibria. Unsophisticated Buyers. Lazy Participants. Why Simplify?. Milgrom’s. Simplification . Thm. .. Cody Dunne and Ben Shneiderman. {cdunne, ben}@. cs.umd.edu. 30. th. . Annual . Human-Computer Interaction Lab Symposium, May 22–23, 2013. College Park, . MD. Who Uses Network Analysis. Network Analysis is Hard. Kevin L. Ard, MD, MPH. October 20, 2016. Learning objectives. Summarize the indications for and management of pre- and post-exposure prophylaxis. Understand clinical uncertainties in pre-exposure prophylaxis management. Treatment-naïve Patients . Clinical Instructor, Harvard Medical School. Director of Research, CRI New England. Vice Chair, INSIGHT Scientific Steering Committee. Boston, USA . Calvin Cohen, MD, MSc. Access and Rational Use. Blood, Radiological and Pharmaceutical Services. Regulatory System Strengthening. Systems approach/ Across all technologies. Contemplate the specificities off specific technologies. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Nithya Srinivas. 1. , John Fallon. 1. , Craig Sykes. 1. , Nicole White. 1. , Amanda Schauer. 1. , Lou Adamson. 2. , Michelle Matthews. 1. , Paul Luciw. 2. , Phil Smith. 1. , Angela DM Kashuba. 1. 1. University of North Carolina at Chapel Hill, Chapel Hill, United States, . Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Text Simplification David Kauchak CS159 – Spring 2019 Collaborators: Will Coster , Dan Feblowitz and Gondy Leroy Admin Final projects Wednesday’s lecture Text simplification Any intelligent fool can make things bigger, more complex, and more violent. It takes a touch of genius and a lot of courage to move in the opposite direction. . SSAT-029 STUDY . Switch to Etravirine from Efavirenz Due to CNS Toxicity . SSAT-029: Design. Source: Waters L, et al. . AIDS. 2011;25:65-71.. Immediate. . Switch Arm. Etravirine. + 2NRTI. (n = 20). FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg. SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed .

Download Document

Here is the link to download the presentation.
"Simplification to Efavirenz-Tenofovir DF-Emtricitabine"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents